BACKGROUND: Cryptococcal meningitis can occur in persons with less-apparent immunosuppression. We evaluated clinical characteristics and outcomes of persons with HIV-related Cryptococcus presenting with higher CD4 counts. METHODS: We enrolled 736 participants from 2 prospective cohorts in Uganda and South Africa from November 2010 to May 2017. We compared participants with CD4 <50, 50-99, or ≥100 cells/μL by clinical characteristics, cerebrospinal fluid (CSF) parameters, and 18-week survival. RESULTS: Among first episode of cryptococcosis, 9% presented with CD4 ≥100 cells/μL. Participants with CD4 ≥100 cells/μL presented more often with altered mental status (52% vs 39%; P = .03) despite a 10-fold lower initial median CSF fungal burden of 7850 (interquartile range [IQR] 860-65500) versus 79000 (IQR 7400-380000) colony forming units/mL (P < .001). Participants with CD4 ≥100 cells/μL had higher median CSF levels of interferon-gamma, interleukin (IL)-6, IL-8, and IL-13, and lower monocyte chemokine, CCL2 (P < .01 for each). Death within 18 weeks occurred in 47% with CD4 <50, 35% with CD4 50-99, and 40% with CD4 ≥100 cells/μL (P = .04). CONCLUSION: HIV-infected individuals developing cryptococcal meningitis with CD4 ≥100 cells/μL presented more frequently with altered mental status despite having 10-fold lower fungal burden and with greater Th2 (IL-13) immune response. Higher CD4 count was protective despite an increased propensity for immune-mediated damage, consistent with damage-response framework. CLINICAL TRIAL REGISTRATION: NCT01075152 and NCT01802385.
BACKGROUND: Cryptococcal meningitis can occur in persons with less-apparent immunosuppression. We evaluated clinical characteristics and outcomes of persons with HIV-related Cryptococcus presenting with higher CD4 counts. METHODS: We enrolled 736 participants from 2 prospective cohorts in Uganda and South Africa from November 2010 to May 2017. We compared participants with CD4 <50, 50-99, or ≥100 cells/μL by clinical characteristics, cerebrospinal fluid (CSF) parameters, and 18-week survival. RESULTS: Among first episode of cryptococcosis, 9% presented with CD4 ≥100 cells/μL. Participants with CD4 ≥100 cells/μL presented more often with altered mental status (52% vs 39%; P = .03) despite a 10-fold lower initial median CSF fungal burden of 7850 (interquartile range [IQR] 860-65500) versus 79000 (IQR 7400-380000) colony forming units/mL (P < .001). Participants with CD4 ≥100 cells/μL had higher median CSF levels of interferon-gamma, interleukin (IL)-6, IL-8, and IL-13, and lower monocyte chemokine, CCL2 (P < .01 for each). Death within 18 weeks occurred in 47% with CD4 <50, 35% with CD4 50-99, and 40% with CD4 ≥100 cells/μL (P = .04). CONCLUSION: HIV-infected individuals developing cryptococcal meningitis with CD4 ≥100 cells/μL presented more frequently with altered mental status despite having 10-fold lower fungal burden and with greater Th2 (IL-13) immune response. Higher CD4 count was protective despite an increased propensity for immune-mediated damage, consistent with damage-response framework. CLINICAL TRIAL REGISTRATION: NCT01075152 and NCT01802385.
Authors: Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware Journal: Lancet Infect Dis Date: 2017-05-05 Impact factor: 25.071
Authors: Sarah Lofgren; Kathy H Hullsiek; Bozena M Morawski; Henry W Nabeta; Reuben Kiggundu; Kabanda Taseera; Abdu Musubire; Charlotte Schutz; Mahsa Abassi; Nathan C Bahr; Lillian Tugume; Conrad Muzoora; Darlisha A Williams; Melissa A Rolfes; Sruti S Velamakanni; Radha Rajasingham; Graeme Meintjes; Joshua Rhein; David B Meya; David R Boulware Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Lori M Neal; Enze Xing; Jintao Xu; Jessica L Kolbe; John J Osterholzer; Benjamin M Segal; Peter R Williamson; Michal A Olszewski Journal: MBio Date: 2017-11-21 Impact factor: 7.867
Authors: James E Scriven; Lisa M Graham; Charlotte Schutz; Thomas J Scriba; Katalin A Wilkinson; Robert J Wilkinson; David R Boulware; Britta C Urban; Graeme Meintjes; David G Lalloo Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: Anil A Panackal; Kim C Williamson; Diederik van de Beek; David R Boulware; Peter R Williamson Journal: MBio Date: 2016-01-26 Impact factor: 7.867
Authors: Mark W Tenforde; Thandi Milton; Ikanyeng Rulaganyang; Charles Muthoga; Leabaneng Tawe; Tom Chiller; Gregory Greene; Alexander Jordan; Christopher G Williams; Leah Owen; Tshepo B Leeme; Amber Boose; Julia Ngidi; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Mark W Tenforde; Graeme Meintjes; Margaret Mokomane; Thomas S Harrison; Madisa Mine; Joseph N Jarvis Journal: AIDS Date: 2019-07-15 Impact factor: 4.177
Authors: Matthew F Pullen; Katherine Huppler Hullsiek; Joshua Rhein; Abdu K Musubire; Lillian Tugume; Edwin Nuwagira; Mahsa Abassi; Kenneth Ssebambulidde; Edward Mpoza; Ruben Kiggundu; Andrew Akampurira; Henry W Nabeta; Charlotte Schutz; Emily E Evans; Radha Rajasingham; Caleb P Skipper; Katelyn A Pastick; Darlisha A Williams; Bozena M Morawski; Ananta S Bangdiwala; Graeme Meintjes; Conrad Muzoora; David B Meya; David R Boulware Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Xinmin Xu; Pengcheng Du; Huizhu Wang; Xiaoling Yang; Tingting Liu; Yuanyuan Zhang; Yajie Wang Journal: J Int Med Res Date: 2021-05 Impact factor: 1.671
Authors: Anna M Stadelman; Kenneth Ssebambulidde; Lillian Tugume; Katelyn A Pastick; Kathy Huppler Hullsiek; Sarah Lofgren; Edwin Nuwagira; Emily E Evans; Darlisha A Williams; Conrad Muzoora; David B Meya; Radha Rajasingham; Joshua Rhein; David R Boulware Journal: Med Mycol Date: 2021-07-06 Impact factor: 4.076